Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.58 CHF | +0.17% | +3.97% | +26.20% |
05-03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
04-09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
Sales 2024 * | 182M 201M 15.92B | Sales 2025 * | 206M 227M 18.02B | Capitalization | 537M 593M 47.06B |
---|---|---|---|---|---|
Net income 2024 * | 23M 25.41M 2.01B | Net income 2025 * | 35M 38.67M 3.07B | EV / Sales 2024 * | 3.27 x |
Net Debt 2024 * | 57.88M 63.94M 5.07B | Net Debt 2025 * | 12.51M 13.82M 1.1B | EV / Sales 2025 * | 2.67 x |
P/E ratio 2024 * |
22.3
x | P/E ratio 2025 * |
18.8
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
1 day | +0.17% | ||
1 week | +3.97% | ||
Current month | +12.78% | ||
1 month | +9.46% | ||
3 months | +19.12% | ||
6 months | +24.62% | ||
Current year | +26.20% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 31/08/14 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 31/12/08 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 30/04/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 26/04/17 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 31/12/21 |
Director/Board Member | 69 | 08/04/13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 34 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
15/05/24 | 44.55 | +0.11% | 7 719 |
14/05/24 | 44.5 | +3.25% | 40,475 |
13/05/24 | 43.1 | +0.35% | 23,536 |
10/05/24 | 42.95 | +0.23% | 32,989 |
08/05/24 | 42.85 | +5.28% | 61,838 |
Delayed Quote Swiss Exchange, May 15, 2024 at 09:56 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.20% | 593M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+47.07% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- BSLN Stock